Physician profile
Lydia Shajenko
NPI 1841289634
$84,722.32
in general payments reported to CMS, 2019-2025
63 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,315 · 2020: $20K · 2021: $27K · 2022: $17K · 2023: $12K · 2024: $5,138 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $6,793 · Travel and Lodging: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,775.00 |
| Food and Beverage | $6,792.80 |
| Travel and Lodging | $521.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $47,899.83 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Allergan, INC. | $22,980.65 | 2019-2021 | |
| Livanova USA, INC. | $1,660.73 | 2019-2022 | |
| Pfizer INC. | $1,084.39 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,057.04 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Scilex Pharmaceuticals INC. | $1,036.76 | 2019-2025 | Ztlido |
| Biohaven Pharmaceutical Holding Company Ltd. | $728.84 | 2022 | |
| Lilly USA, LLC | $716.07 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Pacira Pharmaceuticals Incorporated | $657.04 | 2023-2025 | Iovera, Zilretta, Exparel |
| Lundbeck LLC | $618.35 | 2019-2025 | Vyepti |
| Horizon Therapeutics Plc | $467.24 | 2019-2021 | |
| Amgen INC. | $437.13 | 2019-2022 | |
| Corium, LLC | $353.20 | 2022-2024 | Azstarys |
| Biogen, INC. | $271.42 | 2020-2025 | Leqembi |
| Genzyme Corporation | $261.52 | 2019-2022 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lydia Shajenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.